Skip to main content
TIANJIN LISHENG PHARMACEUTICAL CO.,LTD. logo

TIANJIN LISHENG PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 002393 ISIN · CNE100000NJ9 LEI · 300300OSPF1K59AWRD81 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2026-05-07 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 002393

About TIANJIN LISHENG PHARMACEUTICAL CO.,LTD.

https://www.lishengpharma.com

Tianjin Lisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of chemical pharmaceutical preparations. The company's extensive product portfolio encompasses a wide range of therapeutic areas, including cardiovascular health, anti-infectives, vitamins, and metabolic disorders. Notable products include Indapamide tablets, which are widely utilized for hypertension management. Operating with advanced manufacturing facilities that adhere to international Good Manufacturing Practice (GMP) standards, the organization focuses on delivering high-quality generic and innovative medications. Its operations integrate the entire value chain from active pharmaceutical ingredient (API) sourcing to final dosage form production, serving both domestic and global healthcare markets. The company maintains a strong commitment to technological innovation and quality control to ensure the efficacy and safety of its medicinal offerings.

Recent filings

Filing Released Lang Actions
关于公司高级管理人员减持股份预披露公告
Director's Dealing Classification · 100% confidence The document is a public announcement regarding a senior management personnel's plan to reduce their shareholding in the company. It details the individual's current shareholding, the planned reduction amount, the method and timing of the reduction, and compliance with relevant regulations. There are no financial statements, earnings data, or report attachments. The content fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on the share reduction plan by a senior executive, confirming it is not a full financial report or other type of filing.
2026-05-07 Chinese
天津力生制药股份有限公司2025年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金存放与使用情况专项报告" which translates to a "Special Report on the Deposit and Use of Raised Funds" for the year 2025. It details the company's fundraising activities, the amounts raised, the management and use of these funds, changes in investment projects, and the purchase of financial products with idle raised funds. The document references regulatory approvals, shareholder meetings, and board resolutions related to the use of raised capital. It is a detailed report focused specifically on the management and use of capital raised through share issuance, rather than a general annual or quarterly financial report. This type of document fits the category of a Capital/Financing Update (CAP), as it provides updates on fundraising, capital usage, and related financial activities. The document length and detail confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is CAP with high confidence.
2026-03-24 Chinese
关于公司2026年使用闲置募集资金进行现金管理额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Tianjin Lisheng Pharmaceutical Co., Ltd. regarding the company's plan to use idle raised funds (募集资金) for cash management purposes. It details the amount of idle funds, the intended use for safe and liquid investment products, the approval process including board and independent directors' opinions, and compliance with regulatory guidelines. The document does not contain financial statements or detailed financial performance data but is a disclosure about the use of funds and related approvals. It is a regulatory announcement about capital management activities rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is substantive and not merely a report publication announcement or certification. Hence, CAP is the most appropriate classification.
2026-03-24 Chinese
关于公司董事2025年度薪酬情况及2026年度薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the company's board of directors' remuneration for the year 2025 and the remuneration plan for 2026. It details the salary standards, payment methods, and related policies for independent and non-independent directors. The document also mentions that the remuneration proposal was submitted to the shareholders' meeting for approval due to the directors' conflict of interest. There is no financial report or detailed financial data presented, nor is it a full annual report or interim report. The content focuses specifically on board remuneration information, which fits the category of Remuneration Information (DEF 14A). The document length is short (1536 characters), and it is not merely an announcement of a report but contains substantive remuneration details. Therefore, the appropriate classification is DEF 14A with high confidence.
2026-03-24 Chinese
2025年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2025 年度董事会工作报告' which translates to '2025 Annual Board Work Report'. It contains a detailed review of the company's strategic progress, financial performance, governance, risk management, and outlook for 2026. The content focuses on the board's activities, strategic decisions, governance improvements, and future plans. It does not present full financial statements or quarterly results but rather a comprehensive narrative from the board about the company's operations and governance over the year. This matches the description of a Board/Management Information report, which includes announcements or reports on board activities and management decisions. The document length (6775 characters) and detailed content support it being a substantive report rather than a brief announcement or certification. Therefore, the appropriate classification is MANG (Board/Management Information).
2026-03-24 Chinese
控股股东及其他关联方资金占用情况的专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a "专项说明" (special explanation) regarding the use of funds by controlling shareholders and related parties of Tianjin Lisheng Pharmaceutical Co., Ltd. It is issued by Da Hua Certified Public Accountants and references the audit of the company's 2025 financial statements, including balance sheets and profit statements, with an unqualified audit opinion issued on March 24, 2026. The document specifically addresses compliance with regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding non-operating fund occupation and related party transactions. It includes detailed tables summarizing non-operating fund occupation and related party fund transactions for the year 2025. The document is a standalone audit-related report focusing on a specific regulatory disclosure about related party fund occupation, not a full annual report or interim report. It is not a general regulatory filing or a report publication announcement because it contains substantive audited data and detailed tables. Therefore, it fits the category of an Audit Report / Information (AR) as it is a specialized audit-related disclosure report.
2026-03-24 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.